RT Journal Article
SR Electronic
T1 Making the invisible enemy visible
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.10.07.307546
DO 10.1101/2020.10.07.307546
A1 Tristan Croll
A1 Kay Diederichs
A1 Florens Fischer
A1 Cameron Fyfe
A1 Yunyun Gao
A1 Sam Horrell
A1 Agnel Praveen Joseph
A1 Luise Kandler
A1 Oliver Kippes
A1 Ferdinand Kirsten
A1 Konstantin Müller
A1 Kristoper Nolte
A1 Alex Payne
A1 Matthew G. Reeves
A1 Jane Richardson
A1 Gianluca Santoni
A1 Sabrina Stäb
A1 Dale Tronrud
A1 Christopher Williams
A1 Andrea Thorn
YR 2020
UL http://biorxiv.org/content/early/2020/10/07/2020.10.07.307546.abstract
AB During the COVID-19 pandemic, structural biologists have rushed to solve the structures of the 28 proteins encoded by the SARS-CoV-2 genome in order to understand the viral life cycle and enable structure-based drug design. In addition to the 200 structures from SARS-CoV previously solved, 367 structures covering 16 of the viral proteins have been released in the span of only 6 months.These structural models serve as basis for research worldwide to understand how the virus hijacks human cells, for structure-based drug design and to aid in the development of vaccines. However, errors often occur in even the most careful structure determination - and are even more common among these structures, which were solved under immense pressure.From the beginning of the pandemic, the Coronavirus Structural Taskforce has categorized, evaluated and reviewed all of these experimental protein structures in order to help downstream users and original authors. Our website also offers improved models for many key structures, which have been used by Folding@Home, OpenPandemics, the EU JEDI COVID-19 challenge, and others. Here, we describe our work for the first time, give an overview of common problems, and describe a few of these structures that have since acquired better versions in the worldwide Protein Data Bank, either from new data or as depositor re-versions using our suggested changes.Competing Interest StatementThe authors have declared no competing interest.